Dexamethasone Sodium Phosphate

• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended
  2022-501396-62-00 Phase III 7 countries Regeneron Pharmaceuticals Inc.
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended
  2022-502975-45-00 Phase III 9 countries Pharma Mar S.A.
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto… Ended
  2022-502322-41-00 Phase III 6 countries F. Hoffmann-La Roche AG
• A Clinical Study to evaluate the long-term safety of Daratumumab in combination with standard bone marrow cancer treatment regiments Ended
  2022-500138-27-01 Phase III 9 countries Janssen - Cilag International
• A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis Ended
  2023-507069-25-00 Phase II 6 countries Janssen - Cilag International
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended
  2024-518304-53-00 Phase III 6 countries European Myeloma Network B.V.
• A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended
  2024-513397-21-00 Phase II 1 country Emn Trial Office S.r.l. Impresa Sociale
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal… Ended
  2024-513422-38-00 Phase III 8 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended
  2023-507419-37-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended
  2023-510537-28-00 Phase III 9 countries Glaxosmithkline Research & Development Limited
• Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended
  2023-509550-55-00 Phase I (FiH) 4 countries Glaxosmithkline Research & Development Limited
• A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended
  2023-506733-30-00 Phase II 1 country Fondazione European Myeloma Network Italy O.N.L.U.S.
• A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended
  2024-513396-41-00 Phase III 1 country Fondazione European Myeloma Network Italy O.N.L.U.S.
• A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended
  2024-511781-37-00 Phase II 3 countries Ceska Myelomova Skupina z.s.; Emn Trial Office S.r.l. Impresa Sociale; European …
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM… Ended
  2024-512049-17-00 Phase IV 1 country Universita' Degli Studi Di Torino
• A study to investigate the clinical benefit of isatuximab in combination with bortezomib, lenalidomide and dexamethasone in adults with newl… Ended
  2024-514417-34-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• Extended Criteria Treatment for Liver Metastases With Heavy Tumour Burden Halted
  2024-512397-95-00 Phase II 1 country Oslo University Hospital HF
• Open-Label Extension of EryDex in A-T (OLE NEAT) Ended
  2024-513618-37-00 Phase III 6 countries Quince Therapeutics S.p.A.
• Efficacy of Intrathecal Morphine for Postoperative Analgesia with or without Suprainguinal Fascia Iliaca Block After Total Hip Arthroplasty:… Ended
  2024-511946-38-00 Phase IV 1 country Centre hospitalier universitaire de Liege
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te… Ended
  2023-509077-23-00 Phase III 7 countries Quince Therapeutics S.p.A.
• FINISHER – Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage Ended
  2024-512314-17-00 Phase III 1 country Rheinische Friedrich-Wilhelms-Universitaet Bonn
• Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic cas… Ended
  2024-511660-89-00 Phase II 1 country Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Showing 25–48 of 48 trials